Table 3. Studies Reporting Outcomes of DCIS by Receipt of Boost vs No Boost.
| Source | Total No. of Patients (Patients Receiving Boost, %) | Median Follow-up, y | Effect of Boost on IBTR |
|---|---|---|---|
| Omlin et al, 2006 a | 316 (52.0) | 6.0 | Yes |
| Yerushalmi et al, 2006 |
75 (25.0) | 6.8 | No |
| Jiveliouk et al, 2009 | 107 (37.3) | 4.0 | No |
| Monteau et al, 2009b | 208 (71.0) | 7.4 | Yes |
| Wai et al, 2011 | 482 (29.8) | 9.3 | No |
| Rakovitch et al, 2013 | 1895 (29.6) | 10.0 | No |
| Meattini et al, 2013 | 389 (48.8) | 7.7 | Yes |
| Wong et al, 2012 | 220 (36.0) | 3.8 | Yes |
| Kim, et al 2014 | 728 (31.9) | 6.7 | No |
| Cutuli et al, 2016 | 819 (48.0) | 7.5 | No |
| Present study | 4131 (64.4) | 9.0 | Yes |
Abbreviations: DCIS, ductal carcinoma in situ; IBTR, ipsilateral breast tumor recurrence.
a
Included only patients with DCIS younger than 45 years.
b
Cohort included patients with DCIS with close and focally positive margins.